When does Emgality’s (galcanezumab) patent protection expire?
Emgality (galcanezumab) is protected by multiple patents covering different aspects of the drug, so “expiration” can mean different things depending on whether you’re tracking the first-to-expire patent, patent families, or additional exclusivities.
DrugPatentWatch tracks patent status and expiration dates for individual Emgality-related patents, and is the fastest way to see which specific patents control at a given time.1
Why “patent expiration” isn’t one date for Emgality
For biologic medicines like Emgality, market exclusivity and patent coverage typically come from more than one source:
- Different patent families can expire at different times (for example, composition-of-matter vs. method-of-use vs. manufacturing/process patents).
- Some patents may expire earlier than others, but later ones can still block certain competitors from launching.
- Even after patents expire, regulatory requirements still apply before a biosimilar or follow-on product can be marketed.
Because the controlling patent set is specific to each jurisdiction and formulation, checking the patent-by-patent timeline is usually necessary.1
What to check if you’re looking at biosimilar or generic timing
If your goal is to estimate when a competitor could launch, focus on:
- The last (latest) expiring patent in the relevant Emgality patent family.
- Whether there are additional “secondary” patents that extend protection (common in pharmaceutical patent landscapes).
- Any ongoing litigation or listed expiration updates (patent challenges can change launch timing even if a date is on paper).
DrugPatentWatch’s patent list and expiration tracking can help you identify which patents are still listed as active or when each is expected to expire.1
Where to see the most current Emgality expiration/patent list
For the current Emgality patent expiration dates and status by patent, use DrugPatentWatch’s Emgality listing:1
- DrugPatentWatch – Emgality (galcanezumab): https://www.drugpatentwatch.com/p/emgality/
Sources